22 results about "Bifidobacterium lactis" patented technology

The application discloses a preparation method and application of a composite strain of a sugar-controlling probiotic, and belongs to the technical field of microorganisms. The method comprises the steps of strain stock solution preparation, anaerobic culture, pH value determination and regulation, and composite strain proportioning. Through a dynamic shunting mechanism with pH value 4.3 as a threshold, the culture solution lower than the value is subjected to re-acidification treatment, and the culture solution higher than the value is subjected to differential dilution and coating operation. Finally, Lactobacillus gasseri, Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Bifidobacterium breve, Bifidobacterium lactis and Bifidobacterium longum are mixed at a preset ratio, and a sustained-release agent is added for storage. The method can significantly improve the screening efficiency of target probiotics, the stability of the composite preparation and the blood glucose regulation effect, and can be widely applied to the development of sugar-controlling probiotic products.

The present application provides a kind of nutritional composition and its application in the preparation of protecting brain barrier health product.The nutritional composition provided by the present application includes animal bifidobacterium lactis subsp CP-9 and 3'-sialyllactose, the present application has been confirmed from histological level: the expression of occludin and claudin-5 in brain tissue can be improved after the nutritional composition of animal bifidobacterium lactis subsp CP-9 and 3'-sialyllactose is applied to organism, so as to strengthen the integrity and occlusion of brain barrier structure, promote the maturation and function perfection of blood-brain barrier, cerebrospinal fluid barrier and other brain barrier system, to realize the effect of enhancing brain barrier function, promoting brain barrier development and other maintenance brain barrier health.

The application discloses a Bifidobacterium lactis specific protein antibody, an antibody conjugated magnetic bead and application. The antibody is a monoclonal antibody BL1, comprising a heavy chain variable region and a light chain variable region, and the amino acid sequences of the heavy chain variable region and the light chain variable region are shown in SEQ ID NO: 3 and 4 respectively. The antibody conjugated magnetic bead is coupled by the monoclonal antibody BL1 and activated carboxyl magnetic beads. The antibody conjugated magnetic bead can specifically enrich Bifidobacterium lactis, has high enrichment efficiency, simple enrichment operation, and can be applied to identification of metabolic products of Bifidobacterium lactis, and can be used for qualitative and quantitative analysis.

The invention provides a composition for improving the intestinal bacterial phase and prolonging the colonization rate of beneficial bacteria in the intestinal tract, the composition comprises Bifidobacterium lactis GKK2, and the composition can be used for improving the intestinal bacterial phase, promoting the colonization rate of the beneficial bacteria in the intestinal tract and prolonging the activity of the beneficial bacteria in the intestinal tract.

This invention provides the application of *Bifidobacterium animalis* subsp. lactis CP-9 in the preparation of compositions that promote neurodevelopment and alleviate cognitive impairment and nerve damage. This invention discovers that *Bifidobacterium animalis* subsp. lactis CP-9 can improve abnormal neurodevelopment, cognitive impairment, and nerve damage, and has a protective effect on the nervous system and overall health. This novel application expands the application scope of *Bifidobacterium animalis* subsp. lactis as a probiotic, and is of great significance for further exploring the functions of probiotics and developing probiotics with higher nutritional and health benefits. It also opens up new avenues and solutions for protecting nervous system health and preventing nervous system diseases through dietary strategies.

The present application provides a kind of nutritional composition in the application of the product for improving learning, memory and cognitive ability.The nutritional composition includes animal bifidobacterium lactis subsp.CP-9 and 3'-sialyllactose.Animal bifidobacterium lactis subsp.CP-9 and 3'-sialyllactose can synergistically enhance the memory retention ability of the body, reduce the degree of learning and memory errors, and up-regulate the expression of oligodendrocyte transcription factor 2 coding gene, myelin basic protein coding gene and brain-derived neurotrophic factor coding gene, realize the double regulation of myelin formation and neurotrophic in hippocampus region of brain, synergistically improve the neural plasticity of central nervous system through gut-brain axis pathway, and then double improve the learning, memory and cognitive function of the body from the behavior and molecular level.

An oat preparation, an oat product comprising the oat preparation, a preparation method therefor and the use thereof. The oat preparation is obtained by fermenting a fermentation broth; the fermentation broth comprises a fermentation substrate and a starter culture; the fermentation substrate mainly consists of hydrolyzed oat bran; the starter culture comprises lactobacillus reuteri, lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium lactis and lactobacillus rhamnosus, and comprises streptococcus salivarius subsp. thermophilus and lactobacillus delbrueckii subsp. bulgaricus.

The application discloses an animal bifidobacterium lactis subsp. RO-1 and products and applications thereof, and belongs to the technical field of microorganisms. The technical problem to be solved is to provide an animal bifidobacterium lactis subsp. capable of preventing the formation and recurrence of kidney stones. The technical solution is to provide an animal bifidobacterium lactis subsp. RO-1, and the preservation number is CGMCC No. 38427. The animal bifidobacterium lactis subsp. RO-1 can regulate urine stone-related indexes, down-regulate urine oxalic acid and urine calcium-related creatinine ratio, weaken the generation inducement of calcium oxalate crystals, reduce urea nitrogen and urine protein creatinine ratio, improve glomerular filtration capacity, reduce nitrogen waste accumulation and protein leakage, reduce the damage of a kidney filtration barrier, repair the structural integrity of a renal tubule, and significantly reduce the kidney stone formation rate.

This invention discloses the application of *Bifidobacterium animalis* subsp. *lactamase* GOLDGUT-BB21 in lowering uric acid, belonging to the field of biomedical technology. This strain is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 29347, on December 18, 2023, and is taxonomically named *Bifidobacterium animalis* subsp. *lactamase*. Bifidobacterium animalis subsp.lactis The present invention, Bifidobacterium lactis subspecies GOLDGUT-BB21, exhibits outstanding effects in lowering uric acid, improving renal function, regulating intestinal flora, and enhancing the intestinal barrier. It is safe, mild, and has multi-target synergistic characteristics, and can provide a highly efficient and promising microecological solution for nutritional intervention in hyperuricemia and related metabolic abnormalities.

This invention provides an application of *Bifidobacterium lactis* subspecies BR061 and its postbiotics in regulating mood and promoting digestion and absorption, belonging to the field of microbial and functional development technology. This invention provides *Bifidobacterium lactis* subspecies BR061, with accession number CGMCC No. 37152. This invention further provides the fermentation broth, lyophilized powder, and postbiotics of this *Bifidobacterium lactis* subspecies BR061, as well as their preparation methods, and the application of this *Bifidobacterium lactis* subspecies BR061 and its fermentation broth, lyophilized powder, and postbiotics in regulating mood and promoting digestion and absorption, possessing broad market potential and application prospects.

The application belongs to the technical field of biological medicine, and particularly relates to a functional composition for regulating lipid metabolism and a preparation method and application thereof. The application provides a functional composition for regulating lipid metabolism, which comprises, in mass parts, 10-14 parts of probiotics, 8-12 parts of Opuntia tuna powder, 2-4 parts of mulberry leaf extract, 0.5-1.5 parts of cinnamon, 1-3 parts of chromium, 18-22 parts of xylo-oligosaccharide, 18-22 parts of inulin and 27-35 parts of resistant dextrin; the probiotics comprise Bifidobacterium lactis, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus casei, Lactobacillus acidophilus and Bifidobacterium animalis. The functional composition has a synergistic effect of the components, can promote the colonization of beneficial bacteria, inhibit the growth of harmful bacteria, maintain the balance of intestinal flora, regulate lipid metabolism and be used for preventing and treating diseases related to lipid metabolism.

This invention discloses a probiotic nutritional preparation for enhancing astronauts' immunity and its preparation method, belonging to the field of biomedical technology. The preparation consists of lyophilized Bifidobacterium lactis BL-Immuno97 strain powder, dextran, sodium butyrate, galactooligosaccharides, trehalose, skim milk powder, and microcrystalline cellulose. The mass ratio of β-glucan to sodium butyrate is 3:1 to 4:1, and the viable count is not less than 10 billion CFU / g. The preparation method employs pH-stat controlled fermentation, liquid nitrogen instantaneous freezing, and programmed lyophilization processes to ensure a high viable bacteria survival rate. This invention aims to solve the problems of weak immune targeting, poor activity stability, and process incompatibility of existing probiotic preparations in the space environment. This preparation can maintain a high viable bacteria count for a long time in orbit, significantly improving sIgA levels, NK cell activity, and intestinal flora diversity, effectively maintaining the systemic immune function of astronauts.

The application provides application of animal Bifidobacterium lactis BGI-L99 in prevention and treatment of hormone imbalance and aging related diseases, and belongs to the technical field of biotechnology. The aforementioned animal Bifidobacterium lactis BGI-L99 is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on March 31, 2026, and the preservation number is GDMCC No. 68017. Products prepared from the animal Bifidobacterium lactis BGI-L99 in the examples of the application can effectively prevent and treat sex hormone imbalance related diseases and delay aging related degenerative diseases, including relieving polycystic ovary syndrome and osteoporosis, specifically including improving ovarian function, endocrine disorder, depression, metabolic disorder, inflammatory reaction, abnormal intestinal metabolic product, bone microstructure degradation, imbalance between bone formation and bone resorption and the like.

The application discloses an animal bifidobacterium capable of relieving ulcerative colitis related colorectal cancer and an application thereof, and belongs to the technical field of microorganisms and the technical field of medicines. The application provides an animal bifidobacterium lactis (Bifidobacterium animalis subsp. lactis) CCFM1383 with a preservation number of GDMCC No: 64443. The animal bifidobacterium lactis CCFM1383 can effectively improve the symptoms of ulcerative colitis related colorectal cancer, specifically in relieving the weight loss of mice, improving the survival rate, prolonging the colon length, reducing the number of tumor nodules, reducing the spleen index, reducing the tumor tissue proliferation marker, promoting the apoptosis of tumor cells, regulating the content of inflammatory factors, improving the content of tight junction proteins, inhibiting the expression of cancer signal pathway genes, and improving the content of colon indole propionic acid.

This invention provides a probiotic symbiotic biofilm and its application in the preparation of products for the prevention or adjunctive treatment of alcoholic liver disease, relating to the field of biomaterials technology. The probiotic symbiotic biofilm is composed of *Lactobacillus rhamnosus* (…). Lactobacillus rhamnosus LRa05 and Bifidobacterium lactis ( Bifidobacterium lactis The above two microorganisms were prepared using BLa80. Under co-culture conditions, they can form a dense symbiotic biofilm. The two strains are evenly distributed and intertwined within the biofilm, forming a thicker and more stable three-dimensional structure than a single strain. This symbiotic biofilm structure endows the probiotics with stronger environmental tolerance and intestinal adhesion ability, laying the foundation for their colonization and sustained function in the intestine. It can not only significantly improve alcohol-induced intestinal barrier damage, but also effectively intervene in alcoholic liver disease, providing a new application scenario for the two strains.

In particular, this invention refers to a composition comprising a probiotic combination comprising: a) at least one strain of the genus Lactobacillus selected from the species Lactobacillus plantarum; and c) at least one strain belonging to the genus Bifidobacterium selected from the species Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium infantis; wherein said composition is for use in a method for the prevention and / or treatment of chronic inflammatory bowel disease (Inflammatory Bowel Disease IBD).

This invention relates to the field of biopharmaceutical technology, and in particular to an antibody-targeted modified dual-strain prebiotic delivery system, its preparation method, and its applications. This invention modifies VCAM-1 antibody fragments onto *AKK* bacteria and *Bifidobacterium lactis* Probio-M8, then utilizes fructooligosaccharides and inulin as prebiotics to enhance probiotic metabolism and promote intestinal colonization. Finally, it coats the system with hydroxypropyl methylcellulose phthalate (HPMCP) enteric coating to construct the antibody-targeted modified dual-strain prebiotic delivery system—V-PM8-Am-FI-HPMC. The V-PM8-Am-FI-HPMC provided by this invention can simultaneously achieve intestinal flora regulation, lipid metabolism balance, inflammation suppression, ischemia improvement, and vascular anti-calcification, ultimately achieving the purpose of treating and / or improving atherosclerosis, while ensuring targeting and safety.

The present application relates to the technical field of health food, and in particular to a compound probiotic tablet for sleep aid and mood regulation, a preparation method thereof and application.The compound probiotic tablet comprises animal bifidobacterium lactis subspecies Probio-M8, animal bifidobacterium lactis subspecies Bbm-19, lactobacillus gasseri ProSci-108, lactobacillus gasseri G098, lactobacillus rhamnosus R7970, clostridium tyrobutyricum EC80, flammulina velutipes polysaccharide and excipients, synergistic effects between the flammulina velutipes polysaccharide and the strains are utilized, the types and the amount of the probiotics are reduced, the intestinal flora structure is reshaped, the synthesis of GABA and 5-HT is promoted, the central nervous system is regulated through the intestinal-brain axis, and the effects of sleep aid, mood regulation and improvement of skin water content are significantly improved.Meanwhile, the stability of the probiotic tablet is improved through improvement of the tablet excipients.

A composition for treating insomnia, comprising a probiotic complex and traditional Chinese medicine components. The probiotic complex comprises Lactobacillus plantarum, Bifidobacterium lactis, Lactobacillus crispatus, Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Lactobacillus reuteri, Lactobacillus casei, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus fermentum, Lactobacillus gasseri, Lactococcus lactis, Bifidobacterium longum, Lactobacillus salivarius, Bifidobacterium breve, Streptococcus thermophilus, Lactobacillus paracasei and Lactobacillus helveticus. The traditional Chinese medicine components are semen ziziphi spinosae, bulbus lilii, poria, semen nelumbinis and mori fructus. The composition may further comprise prebiotics selected from L-arabinose, β-glucan, inulin, erythritol, lactitol, vitamin C and γ-aminobutyric acid. The composition can be used for preparing pharmaceutical or food formulations, such as solid beverages, chewable tablets or oral lozenges. Clinical observation shows that the composition has the effect of relieving insomnia.

This invention, entitled "Application of Bifidobacterium animalis subsp. lactis BL-16 and its Astragalus ferment and anti-aging products," belongs to the field of microbial technology. The technical problem to be solved is to provide an anti-aging Bifidobacterium animalis subsp. lactis and its BL-16 fermented Astragalus extract. The key technical point is the application of Bifidobacterium animalis subsp. lactis BL-16 or its fermented Astragalus extract in the preparation of anti-aging compositions. Bifidobacterium animalis subsp. lactis BL-16 and its fermented Astragalus extract can scavenge free radicals in vivo and in vitro and enhance anti-lipid peroxidation capacity, exhibiting good antioxidant and immunomodulatory effects. They can effectively improve survival rate, motility, and reproductive capacity, thus having a good effect on delaying aging.

The present invention provides an oat product obtained by fermenting a fermentation solution comprising a fermentation substrate consisting essentially of hydrolyzed oat bran and a fermenting agent comprising Lactobacillus reuteri, Lactobacillus plantarum, Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus rhamnosus and comprising Streptococcus salivarius subsp. thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The present invention also provides an oat product comprising the oat product and methods of making and uses of the oat product.